Bayer faces second trial over alleged Roundup cancer
risk
Send a link to a friend
[February 25, 2019]
By Tina Bellon
(Reuters) - Bayer AG is set to face a
second U.S. jury over allegations that its popular glyphosate-based weed
killer Roundup causes cancer, six months after the company's share price
was rocked by a $289 million verdict in California state court.
A lawsuit by California resident Edwin Hardeman against the company was
scheduled to begin on Monday in federal rather than state court. The
trial is also a test case for a larger litigation. More than 760 of the
9,300 Roundup cases nationwide are consolidated in the federal court in
San Francisco that is hearing Hardeman's case.
Bayer denies all allegations that Roundup or glyphosate cause cancer,
saying decades of independent studies have shown the world's most widely
used weed killer to be safe for human use and noting that regulators
around the world have approved the product.
Under a January ruling by U.S. District Judge Vince Chhabria, who
presides over the federal litigation, jurors in Hardeman's case will not
initially hear all the evidence presented in last year's California
trial.
Chhabria called evidence by plaintiffs that the company allegedly
attempted to influence regulators and manipulate public opinion "a
distraction" from the science in the cases. He said such evidence should
only go before the jury in a second trial phase that would only take
place if they determined Roundup caused Hardeman's cancer.
Evidence of corporate misconduct was seen as playing a key role in the
finding by a California state court jury in August that Roundup caused
another man's non-Hodgkin's lymphoma and that Bayer's Monsanto unit
failed to warn consumers about the weed killer's cancer risks. That
jury's $289 million damages award was later reduced to $78 million.
[to top of second column] |
A woman uses a Monsanto's Roundup weedkiller spray without
glyphosate in a garden in Ercuis near Paris, France, May 6, 2018.
REUTERS/Benoit Tessier/File Photo
Bayer's share price dropped 10 percent following the verdict and has remained
volatile.
Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to
control poison oak and weeds on his property and sprayed "large volumes" of the
chemical for many years on a regular basis, according to court documents. He was
diagnosed with non-Hodgkin's lymphoma, a cancer of the lymph system, in February
2015 and filed his lawsuit a year later.
But Hardeman has a history of hepatitis C, a risk factor for developing
lymphoma. Bayer in court filings also said the majority of non-Hodgkin's
lymphoma incidents are idiopathic, or have no known cause.
Plaintiffs criticized Chhabria's order dividing the trial and restricting
evidence as "unfair," saying their scientific evidence allegedly showing
glyphosate causes cancer is inextricably linked to Monsanto's alleged wrongful
conduct.
(Reporting by Tina Bellon in New York; Editing by Cynthia Osterman and Jonathan
Oatis)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|